Market closed
Vanda Pharmaceuticals/$VNDA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
Ticker
$VNDA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
203
Website
VNDA Metrics
BasicAdvanced
$269M
Market cap
-
P/E ratio
-$0.29
EPS
0.77
Beta
-
Dividend rate
Price and volume
Market cap
$269M
Beta
0.77
52-week high
$6.75
52-week low
$3.46
Average daily volume
724K
Financial strength
Current ratio
4.853
Quick ratio
4.703
Long term debt to equity
1.014
Total debt to equity
1.467
Interest coverage (TTM)
-41.59%
Management effectiveness
Return on assets (TTM)
-3.64%
Return on equity (TTM)
-3.02%
Valuation
Price to revenue (TTM)
1.403
Price to book
0.5
Price to tangible book (TTM)
0.63
Price to free cash flow (TTM)
-2.175
Growth
Revenue change (TTM)
-9.91%
Earnings per share change (TTM)
-240.92%
3-year revenue growth (CAGR)
-10.73%
3-year earnings per share growth (CAGR)
-21.50%
What the Analysts think about VNDA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Vanda Pharmaceuticals stock.
VNDA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VNDA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VNDA News
AllArticlesVideos
Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
Accesswire·1 month ago
Over 200% Stock Upside - Vanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst
Benzinga·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Vanda Pharmaceuticals stock?
Vanda Pharmaceuticals (VNDA) has a market cap of $269M as of December 14, 2024.
What is the P/E ratio for Vanda Pharmaceuticals stock?
The price to earnings (P/E) ratio for Vanda Pharmaceuticals (VNDA) stock is 0 as of December 14, 2024.
Does Vanda Pharmaceuticals stock pay dividends?
No, Vanda Pharmaceuticals (VNDA) stock does not pay dividends to its shareholders as of December 14, 2024.
When is the next Vanda Pharmaceuticals dividend payment date?
Vanda Pharmaceuticals (VNDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Vanda Pharmaceuticals?
Vanda Pharmaceuticals (VNDA) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.